<Anchor>

US President Trump announced on the 24th that it was a breakthrough in the treatment of Corona 19, and that the FDA of the US Food and Drug Administration had urgently approved plasma treatment. The head of the FDA said that there was a data exaggeration, and there is a controversy over it.

Correspondent Kim Soo-hyung reports from Washington.

<Reporter>

This is a public reflection posted on Twitter by the director of the US Food and Drug Administration.

He said he should have been able to properly explain that he accepts the criticism he has poured on himself, and that the risk that plasma treatment reduces is relative, not absolute.

When President Trump announced that the U.S. FDA had urgently approved plasma treatments and opened a breakthrough in the treatment of COVID-19, he confessed that he had exaggerated the data.

[Steven Korea/US FDA Director (Yesterday): 35 out of 100 people show data that plasma treatment results can save lives. This is very important for patients and their families.]

However, criticism from health experts has poured out for not knowing where these statistics come from.

[Ash Ja/Harvard University Professor: This is a very misrepresentation of the data. These things make me worry that the FDA's scientific review process has been broken.] At the

Republican Convention, praise that the FDA urgently approved plasma treatment to open a new breakthrough in corona treatment continued.

As criticism pours over whether the FDA has succumbed to President Trump's political pressure, concerns have also been raised over whether the vaccine is being screened.